Protagonist Therapeutics, Inc. (PTGX) announced Monday it is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).
from RTT - Biotech https://ift.tt/2IQhyKu
via IFTTT
No comments:
Post a Comment